Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Insulin Infusion Pumps Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 100 pages
- Published: 13-06-2019
Market Overview
The global insulin infusion pump market is set to witness a CAGR of 7.51% during the forecast period. Insulin infusion pumps work as an alternative to the traditional system of daily injections or an insulin pen.
Insulin infusion pumps reduce the large swings in blood glucose level, lessen pain, and deliver more accurately than injections. The scheduling of meal timings is not required when using pumps.
This makes infusion pumps more user-friendly for patients. Insulin therapy is also known as continuous subcutaneous insulin infusion (CSII). It is an efficient and flexible method of insulin delivery.
The insulin pump has evolved and is more reliable than it was previously. CSII technology has witnessed numerous technological advancements, like the integration of continuous glucose monitoring with the pump. Now, insulin pumps can control the algorithm that automatically delivers the insulin, after analyzing the blood glucose reading
Scope of the Report
The insulin market is segmented into the device, infusion set, and reservoir. The report is also segmented into five regions: North America, Asia-Pacific, Europe, Middle East & Africa, and Latin America.
Key Market Trends
The Insulin Pump Market is Growing with the CAGR of 7% in the Forecast Period
Owing to the rising rate of obesity, growing genetic factors for type 2 diabetes, and the increasing number of type 1 diabetes patients, it is likely that the insulin infusion pump market will continue to grow.
Insulin pump use is high among the type 1 population. It is also growing in type 2 patients. The ratio of children to adult, or type 1 to type 2, patient’s usage of insulin pumps varies across countries.
North America Holds the Highest Market Share
North America holds the highest market share in the insulin pump market and is also expected to grow with the highest CAGR, of 9.05% in the forecast period, because of the favorable reimbursement policy. Although the pump and its supplies (tubing, insulin cartridges, and infusion sets) continue to be expensive, insurance coverage has improved considerably over the years.
Competitive Landscape
Animas had to exit the insulin pump market, as the company has admitted that rising competition was the reason for them to leave the market.
Medtronic is the market leader and is expected to maintain its position during the forecast period.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product (Value and Volume 2012-2024)
5.1.1 Insulin Pumps
5.1.2 Infusion Sets
5.1.3 Reservoirs
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume 2012-2024)
5.2.1.1.1 By Insulin Pump Devices
5.2.1.1.2 By Infusion Sets
5.2.1.1.3 By Reservoirs
5.2.1.2 Canada (Value and Volume 2012-2024)
5.2.1.2.1 By Insulin Pump Devices
5.2.1.2.2 By Infusion Sets
5.2.1.2.3 By Reservoirs
5.2.1.3 Rest of North America (Value and Volume 2012-2024)
5.2.1.3.1 By Insulin Pump Devices
5.2.1.3.2 By Infusion Sets
5.2.1.3.3 By Reservoirs
5.2.2 Asia-Pacific
5.2.2.1 Japan (Value and Volume 2012-2024)
5.2.2.1.1 By Insulin Pump Devices
5.2.2.1.2 By Infusion Sets
5.2.2.1.3 By Reservoirs
5.2.2.2 South Korea (Value and Volume 2012-2024)
5.2.2.2.1 By Insulin Pump Devices
5.2.2.2.2 By Infusion Sets
5.2.2.2.3 By Reservoirs
5.2.2.3 China (Value and Volume 2012-2024)
5.2.2.3.1 By Insulin Pump Devices
5.2.2.3.2 By Infusion Sets
5.2.2.3.3 By Reservoirs
5.2.2.4 India (Value and Volume 2012-2024)
5.2.2.4.1 By Insulin Pump Devices
5.2.2.4.2 By Infusion Sets
5.2.2.4.3 By Reservoirs
5.2.2.5 Australia (Value and Volume 2012-2024)
5.2.2.5.1 By Insulin Pump Devices
5.2.2.5.2 By Infusion Sets
5.2.2.5.3 By Reservoirs
5.2.2.6 Vietnam (Value and Volume 2012-2024)
5.2.2.6.1 By Insulin Pump Devices
5.2.2.6.2 By Infusion Sets
5.2.2.6.3 By Reservoirs
5.2.2.7 Malaysia (Value and Volume 2012-2024)
5.2.2.7.1 By Insulin Pump Devices
5.2.2.7.2 By Infusion Sets
5.2.2.7.3 By Reservoirs
5.2.2.8 Indonesia (Value and Volume 2012-2024)
5.2.2.8.1 By Insulin Pump Devices
5.2.2.8.2 By Infusion Sets
5.2.2.8.3 By Reservoirs
5.2.2.9 Philippines (Value and Volume 2012-2024)
5.2.2.9.1 By Insulin Pump Devices
5.2.2.9.2 By Infusion Sets
5.2.2.9.3 By Reservoirs
5.2.2.10 Thailand (Value and Volume 2012-2024)
5.2.2.10.1 By Insulin Pump Devices
5.2.2.10.2 By Infusion Sets
5.2.2.10.3 By Reservoirs
5.2.2.11 Rest of Asia-Pacific (Value and Volume 2012-2024)
5.2.2.11.1 By Insulin Pump Devices
5.2.2.11.2 By Infusion Sets
5.2.2.11.3 By Reservoirs
5.2.3 Europe
5.2.3.1 United Kingdom (Value and Volume 2012-2024)
5.2.3.1.1 By Insulin Pump Devices
5.2.3.1.2 By Infusion Sets
5.2.3.1.3 By Reservoirs
5.2.3.2 France (Value and Volume 2012-2024)
5.2.3.2.1 By Insulin Pump Devices
5.2.3.2.2 By Infusion Sets
5.2.3.2.3 By Reservoirs
5.2.3.3 Germany (Value and Volume 2012-2024)
5.2.3.3.1 By Insulin Pump Devices
5.2.3.3.2 By Infusion Sets
5.2.3.3.3 By Reservoirs
5.2.3.4 Italy (Value and Volume 2012-2024)
5.2.3.4.1 By Insulin Pump Devices
5.2.3.4.2 By Infusion Sets
5.2.3.4.3 By Reservoirs
5.2.3.5 Spain (Value and Volume 2012-2024)
5.2.3.5.1 By Insulin Pump Devices
5.2.3.5.2 By Infusion Sets
5.2.3.5.3 By Reservoirs
5.2.3.6 Russia (Value and Volume 2012-2024)
5.2.3.6.1 By Insulin Pump Devices
5.2.3.6.2 By Infusion Sets
5.2.3.6.3 By Reservoirs
5.2.3.7 Rest of Europe (Value and Volume 2012-2024)
5.2.3.7.1 By Insulin Pump Devices
5.2.3.7.2 By Infusion Sets
5.2.3.7.3 By Reservoirs
5.2.4 Latin America
5.2.4.1 Mexico (Value and Volume 2012-2024)
5.2.4.1.1 By Insulin Pump Devices
5.2.4.1.2 By Infusion Sets
5.2.4.1.3 By Reservoirs
5.2.4.2 Brazil (Value and Volume 2012-2024)
5.2.4.2.1 By Insulin Pump Devices
5.2.4.2.2 By Infusion Sets
5.2.4.2.3 By Reservoirs
5.2.4.3 Rest of Latin America (Value and Volume 2012-2024)
5.2.4.3.1 By Insulin Pump Devices
5.2.4.3.2 By Infusion Sets
5.2.4.3.3 By Reservoirs
5.2.5 Middle East & Africa
5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
5.2.5.1.1 By Insulin Pump Devices
5.2.5.1.2 By Infusion Sets
5.2.5.1.3 By Reservoirs
5.2.5.2 Iran (Value and Volume 2012-2024)
5.2.5.2.1 By Insulin Pump Devices
5.2.5.2.2 By Infusion Sets
5.2.5.2.3 By Reservoirs
5.2.5.3 Egypt (Value and Volume 2012-2024)
5.2.5.3.1 By Insulin Pump Devices
5.2.5.3.2 By Infusion Sets
5.2.5.3.3 By Reservoirs
5.2.5.4 Oman (Value and Volume 2012-2024)
5.2.5.4.1 By Insulin Pump Devices
5.2.5.4.2 By Infusion Sets
5.2.5.4.3 By Reservoirs
5.2.5.5 South Africa (Value and Volume 2012-2024)
5.2.5.5.1 By Insulin Pump Devices
5.2.5.5.2 By Infusion Sets
5.2.5.5.3 By Reservoirs
5.2.5.6 Rest of Middle East & Africa (Value and Volume 2012-2024)
5.2.5.6.1 By Insulin Pump Devices
5.2.5.6.2 By Infusion Sets
5.2.5.6.3 By Reservoirs
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Medtronic
7.1.2 Insulet
7.1.3 Roche
7.1.4 Animas
7.1.5 Tandem
7.1.6 Ypsomed
7.1.7 Cellnovo
7.2 COMPANY SHARE ANALYSIS
7.2.1 Roche
7.2.2 Animas
7.2.3 Medtronic
7.2.4 Others
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product (Value and Volume 2012-2024)
Insulin Pumps
Infusion Sets
Reservoirs
Geography
North America
United States (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Canada (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Rest of North America (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Asia-Pacific
Japan (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
South Korea (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
China (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
India (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Australia (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Vietnam (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Malaysia (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Indonesia (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Philippines (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Thailand (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Rest of Asia-Pacific (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Europe
United Kingdom (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
France (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Germany (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Italy (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Spain (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Russia (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Rest of Europe (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Latin America
Mexico (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Brazil (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Rest of Latin America (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Middle East & Africa
Saudi Arabia (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Iran (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Egypt (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Oman (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
South Africa (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Rest of Middle East & Africa (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Asia-Pacific Glucagon like Peptide – 1 (GLP – 1) Agonists Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 100 pages
- Published: 13-06-2019
Market Overview
The GLP-1 drugs are also known as “incretin mimetics,” a hormone that stimulates insulin secretion in response to meals.
GLP-1s are considered an adjunct to diet and exercise, to improve glycemic control in adults with type-2 diabetes mellitus.
Patients with type-2 diabetes have diminished insulin release in response to meals, and it is speculated that they may have defects in the release or action of their incretin hormones.
Diabetes prevalence has increased rapidly in recent decades. It is estimated that in 2007, more than 100 million Asians were living with diabetes. Concurrently with the rise in the diabetic population, obesity is also rising sharply because of economic development, increasing sedentary lifestyles, and nutrition transition.
Asia contributes approximately 60% of the total diabetes patients in the world. The most obvious reason for this is that two of the most populated countries in the world are in Asia, i.e., China and Japan.
Scope of the Report
The Asia-Pacific region suffers from a high burden of diabetes, and its adverse health and economic consequences.
The disease is not only viewed as a serious threat, just from a public health perspective, but also from a development perspective.
With risk factors, such as obesity increasing, and progressively aging populations, the diabetes epidemic is growing, especially in the low- and middle-income countries of the region.
It is one of the most common chronic diseases in China and India. The market is segmented by drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by geography.
Key Market Trends
Ever Increasing Prevalence of Diabetes
China tops the global list of countries for the total number of people with diabetes, followed by India. The number of people with diabetes in Japan has also increased significantly.
According to the IDF in 2013, it is estimated that Japan occupied the 10th position in the IDF list, with 7.2 million people with diabetes.
WHO projects that diabetes is likely to be the seventh leading cause of death by 2030. Almost half of all deaths attributable to high blood glucose occur before the age of 70 years.
The growing prevalence of diabetes is the primary driver for the Asia-Pacific diabetes care market. Additionally, rising awareness regarding diabetes care, the ever-increasing prevalence of obesity, and technological advancements are further driving the market.
Japan is Dominating the GLP-1 Market in the Asia-Pacific Region
Japan holds the highest share in the Asia-Pacific GLP-1 agonist market, followed by China. GLP-1 receptor agonists have effective glucose-lowering efficacies and remarkable weight-loss effects, and are beneficial for diabetes treatment, especially for patients with overweight/obesity.
In Asia-Pacific, the revenue generated by the GLP-1 market was USD 384.04 million in 2017, and the market is expected to grow steadily during the forecast period, at a considerable rate of 15.93%. The growth of the market can be attributed to the fact that the type-2 diabetic population is on the rise and is expected to see further increase in the future, due to the lifestyle choices of individuals.
By brand, Victoza occupies the significant market share, at 62.07%, and it is expected to witness a growth rate of 11.49% during the forecast period. Trulicity held 26.24%, as of 2017.
Trulicity has a growth rate of 25.48% and is expected to reach almost the same overall market value as of Victoza, by 2024.
Competitive Landscape
The Asia-Pacific GLP-1 market is consolidated, with four major manufacturers holding a presence in the region.
Currently, no generic versions of the GLP-1s are available in the market, since the drugs are patent protected. However, Sajjala Bio, Hyderabad, India, recently announced developments in a liraglutide biosimilar, and the company is aiming to launch the product by the end of 2019.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET INDICATORS
5.1 Type-1 Diabetes Population (2012-2024)
5.2 Type-2 Diabetes Population (2012-2024)
6 MARKET SEGMENTATION
6.1 By Drug
6.1.1 Exenatide
6.1.1.1 Byetta (Value and Volume, 2012-2024)
6.1.1.2 Bydureon (Value and Volume, 2012-2024)
6.1.2 Liraglutide
6.1.2.1 Victoza (Value and Volume, 2012-2024)
6.1.3 Lixisenatide
6.1.3.1 Lyxumia (Value and Volume, 2012-2024)
6.1.4 Dulaglutide
6.1.4.1 Trulicity (Value and Volume, 2012-2024)
6.2 Geography
6.2.1 Asia-Pacific
6.2.1.1 Japan (Value and Volume, 2012-2024)
6.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.2 China (Value and Volume, 2012-2024)
6.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.3 Australia (Value and Volume, 2012-2024)
6.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.4 India (Value and Volume, 2012-2024)
6.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.5 South Korea (Value and Volume, 2012-2024)
6.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.6 Malaysia (Value and Volume, 2012-2024)
6.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.7 Indonesia (Value and Volume, 2012-2024)
6.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.8 Thailand (Value and Volume, 2012-2024)
6.2.1.8.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.8.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.9 Philippines (Value and Volume, 2012-2024)
6.2.1.9.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.9.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6.2.1.10 Rest of Asia-Pacific (Value and Volume, 2012-2024)
6.2.1.10.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
6.2.1.10.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Sanofi Aventis
7.1.3 Eli Lilly
7.1.4 Astra Zeneca
7.2 MARKET SHARE ANALYSIS
7.2.1 Novo Nordisk
7.2.2 Sanofi Aventis
7.2.3 Eli Lilly
7.2.4 Astra Zeneca
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Exenatide
Byetta (Value and Volume, 2012-2024)
Bydureon (Value and Volume, 2012-2024)
Liraglutide
Victoza (Value and Volume, 2012-2024)
Lixisenatide
Lyxumia (Value and Volume, 2012-2024)
Dulaglutide
Trulicity (Value and Volume, 2012-2024)
Geography
Asia-Pacific
Japan (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
China (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Australia (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
India (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
South Korea (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Malaysia (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Indonesia (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Thailand (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Philippines (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Asia-Pacific (Value and Volume, 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Medical Alert System/Personal Emergency Response System Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 114 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 114 pages
- Published: 13-06-2019
Market Overview
The propelling factors for the growth of the medical alert system/personal emergency response system market include the increasing aging population, technological developments in healthcare wearables, increasing penetration of smartphones in healthcare and constant innovations in technology, and easy adaptability of PERS devices. Owing to the aforementioned factors, the market is expected to experience a boost during the forecast period.
With the rapid increase in the elderly population, there is a growing need for medical alert systems in the houses. Personal emergency response systems (PERS) are mainly for the older population and people with disabilities to easily call for help in an emergency. They are also widely adopted and used throughout most western countries. Therefore, with the help of medical alert systems, the elderly can age in the comfort of their own homes, and thus, this factor is likely to propel the growth of the overall market.
The current market is also growing due to the increasing adoption of smartphones. The global smartphone penetration is estimated at an all-time high, and thus, smartphones are crucial in one’s daily life, which is a major factor for the growth of the market.
The wearable health industry has also exploded in recent years, and thus this trend is expected to grow rapidly in the coming years. These wearables are used to monitor the health and well-being of people. In addition, there are technological advancements in wearables that may help the patients to adopt medical systems in the coming years.
Scope of the Report
As per the scope of the report, personal emergency response systems (PERS), also known as medical emergency response systems, allow users to call for help during an emergency by pushing a button. Therefore, due to the rapid increase in elderly population, there is a growing need for medical alert systems.
Key Market Trends
Mobile PERS Segment by Type is Expected to Grow the Fastest During the Forecast Period
Mobile PERS is found to be the largest segment as these units possess many advantages over traditional PERS units, which include tracking capabilities via a variety of technologies. In addition, they are also lightweight and durable. They are gaining popularity as they allow senior citizens to lead a more independent and healthy lifestyle.
The increasing demand for medical assistance, especially for the elderly, has also resulted in the increasing adoption of landline PERS, which is likely to result in the growth of the medical alert system market over the forecast period.
Asia-Pacific Holds the Fastest Growth in the Market and is Expected to Follow the Same Trend Over the Forecast Period
Asia-Pacific is estimated to be the fastest-growing region in the overall market over the forecast period, owing to the increasing geriatric population and increasing prevalence of chronic diseases. Also, the need for improved healthcare facilities and an increase in home-based health programs are expected to drive the market. Thus, increasing geriatric population and chronic diseases may lead to the growth of the medical alert system market.
The rising technological advancements, increasing awareness among the people, and increasing investments from foreign players are, therefore, expected to augment the growth of the medical alert system market in the future in this region.
Competitive Landscape
Key players are focusing on expanding their product portfolios to increase their market share. In addition, they are adopting strategies, such as acquisitions and collaborations. There are various companies in the medical alert system market, including ADT Corporation, Bay Alarm Medical, Philips Lifeline, Life Alert Emergency Response Inc., VRI Inc., and many others, which are leading players in the global market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Aging Population Across the World
4.2.2 Technological Developments in Healthcare Wearables
4.2.3 Increasing Penetration of Smartphones in Healthcare
4.2.4 Constant Innovations in Technology and Easy Adaptability of PERS Devices
4.3 Market Restraints
4.3.1 Overall Cost Associated with the System is High
4.3.2 Lack of Know-how Pertaining to the New Technology used in the PERS System
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Landline PERS
5.1.2 Mobile PERS
5.1.3 Other Types
5.2 By End User
5.2.1 Home-based Users
5.2.2 Senior Living Facilities
5.2.3 Assisted Living Facilities
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 ADT Corporation
6.1.2 Bay Alarm Medical
6.1.3 Philips Lifeline (Koninklijke Philips N.V.)
6.1.4 Life Alert
6.1.5 VRI Inc.
6.1.6 Tunstall
6.1.7 Medical Guardian LLC
6.1.8 Alertone Services LLC
6.1.9 Greatcall
6.1.10 Rescue Alert
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type
Landline PERS
Mobile PERS
Other Types
By End User
Home-based Users
Senior Living Facilities
Assisted Living Facilities
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
North America Evaporative Cooling Market – Growth, Trends and Forecast (2019 – 2024)
| Information & Communications Technology | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 13-06-2019 |
- Information & Communications Technology
- Mordor Intelligence
- 100 pages
- Published: 13-06-2019
Market Overview
The North American Evaporative Cooling Market is expected to register a CAGR of over 3.71% during the forecast period 2019 – 2024. The North American region has been witnessing an increasing number of initiatives for sustainable energy management. Therefore, traditional air conditioning is not a feasible option. This factor is driving the popularity of evaporative cooling, which is fast becoming the most efficient option, for cooling large areas or open spaces. Evaporative cooling enables firms to gain cooling benefits without adverse effects on the environment. It has become imperative for firms to adopt sustainable practices for their production and HVAC operations, to mitigate risks of environmental pollution.
Various government standards have been implemented in the region, specifically, in the United States, for the efficient use of energy across commercial and industrial sectors, with evaporative cooling technique. Therefore, the Natural Resources Canada is considering increasing the minimum energy performance standards (MEPS) for evaporative-cooled products, to align with the MEPS in the United States, for those classes of products. As evaporative cooling makes use of a natural process, namely the reduction of air temperature by evaporating water on it, they are the preferred alternative over the traditional cooling technologies.
Evaporative coolers offer several benefits to end users, including energy savings, cost effectiveness, low maintenance, and operational requirements, besides being multifunctional (can be used in an open environment, for cooling, air purification, and ventilation). Thus, owing to favorable regulations for sustainable energy across the region, advancements in technologies and their benefits compared to traditional cooling techniques, are significantly driving the market studied.
The other major driver for the US segment is the adoption of evaporative coolers in data centers. The demand for data centers is growing at a brisk pace in the country, with the rapid adoption of Big Data, digital content, and e-commerce. Keeping these facilities constantly functional is mandatory for multinational companies operating in this space. In addition to reliability, the industry is now seeking energy-efficient solutions that have the potential to lower the operational costs and reduce carbon emissions from data center operations. In 2015, the data centers in the United States consumed more than 110 million Kwh of electricity, equivalent to the output of 500 MW coal-fired power plants.
Scope of the Report
Evaporative cooling is preferred as an alternative over the traditional cooling technologies, as it makes use of a natural process, namely the reduction of air temperature by evaporating water on it. Although it is an age-old process, it has emerged as a viable alternative to conventional air conditioning systems in areas where extremely low temperatures are not required.
Key Market Trends
Commercial is expected to register a Significant Growth
Commercial establishments are required to maintain optimal climatic conditions in order to protect the health and well-being of employees and clients. Commercial entities, such as movie theaters, hospitals, hotels, airports, and malls, among others, generally employ both evaporative coolers and air conditioners depending upon the cooling and ventilation requirements of an enclosure.
Moreover, evaporative air coolers are widely used in the aforementioned commercial establishment’s facilities, as alternatives to air conditioners. Apart from this, the market is expected to be driven by the growing adoption in small to medium enterprises instead of air conditioners, as the cost of air conditioning setup can be significantly high.
Due to the recent surge in demand for data center operations, it has become imperative for HVAC companies to offer cost and energy-efficient solutions for data centers. Data center solution providers are on the lookout for reliable solutions that are able to cut down the overall emissions.
A normal data center usually requires around 0.5 to 50MW of cooling capacity, and due to recent changes in ASHRAE guidelines, the permissible operating temperature has been raised to 27°C. This has been a major driver for the demand of evaporative air coolers in data centers. Additionally, these products do not make use of any refrigerants or CFC’s, which could further reduce the overall carbon footprint for the end-user applications.
Direct cooling is Expected to Hold Major Share
Direct evaporative air cooling is the simplest, oldest, and the most widely used type of evaporative cooling. The fan in the system pulls hot air through a dampened sponge-like pad and distributes the resulting cool air to the interior space either directly, or through ducts. Warm dry air is converted to cool moist air as the heat in the air evaporates the water. It is considered that these evaporative coolants are expected to hold a small niche market, majorly in the southern part of the United States, where relative humidity during July noon is higher than 40%.
The direct evaporative cooling systems are suitable for applications that have large heat-load removal needs and those that are open to using outside air to accomplish this. The major areas of their applications include residential sectors, commercial kitchens, and warehouses where comfort requirements are more relaxed. Hence, the system requirement depends majorly on the end users, and on the specified operational performance requirements. Residential evaporative coolers are majorly of the direct type, however, some indirect systems are also used.
Moreover, small commercial buildings are responsible for an increasing share of the US energy consumption and account for 90% of the total number of commercial buildings in the United Stares. US citizens nearly use 30% of the world’s energy, and in the country, small commercial buildings account for approximately 10% of the country’s energy consumption.
Competitive Landscape
The North American Evaporative Cooling Market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. These major players with prominent share in the market are focusing on expanding their customer base across foreign countries. These companies are leveraging on strategic collaborative initiatives to increase their market share and increase their profitability.
The companies operating in the market are also acquiring start-ups working on Evaporative Cooling technologies to strengthen their product capabilities. In February 2018, SPX Cooling Technologies Inc. announced the new Marley MD Everest counter flow cooling tower. The Marley MD Everest cooling tower is designed to meet HVAC demands and is suitable for a wide range of applications.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Introduction to Market Drivers and Restraints
4.3 Market Drivers
4.4 Market Restraints
4.5 Value Chain / Supply Chain Analysis
4.6 Industry Attractiveness Porters Five Force Analysis
4.6.1 Threat of New Entrants
4.6.2 Bargaining Power of Buyers/Consumers
4.6.3 Bargaining Power of Suppliers
4.6.4 Threat of Substitute Products
4.6.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Cooling
5.1.1 Direct
5.1.2 Indirect
5.1.3 Two Stage
5.2 By Application
5.2.1 Industrial
5.2.2 Commercial
5.2.3 Confinement Farming
5.2.4 Other Applications
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Condair Group AG
6.1.2 Baltimore Aircoil Company Inc. (BAC
6.1.3 Munters Group AB
6.1.4 Colt Group
6.1.5 Phoenix Manufacturing Inc.
6.1.6 Delta Cooling Towers Inc.
6.1.7 SPX Cooling Technologies
6.1.8 Bonaire Group (Celi Group)
7 INVESTMENT ANALYSIS
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Cooling
Direct
Indirect
Two Stage
By Application
Industrial
Commercial
Confinement Farming
Other Applications
3D Cell Culture Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 116 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 116 pages
- Published: 13-06-2019
Market Overview
The 3D cell culture market is witnessing a stable growth due to the factors, like huge investments by life science companies for R&D, development of automated large-scale cell culture systems, and rising need for organ transplantation. Lack of experienced and skilled professionals and budget restriction for small and medium-sized laboratories are factors constraining the growth of the 3D cell culture market. However, increasing focus on regenerative medicine and stem cell is acting as an opportunity in the future. The scaffold-based segment holds the largest market share in the global market. The use of hydrogels in the scaffold-based 3D cell culture is the key factor driving the scaffold-based segment, as they can be derived naturally from protein and ECM components (laminin, fibrin, hyaluronic acid, chitosan, etc.). These gels are also biocompatible.
Scope of the Report
This report analyzes and discusses the 3D cell culture market. The market has been segmented on the basis of technology, application, end user, and geography. Based on technology, the market has been segmented into extracellular matrices (scaffolds), bioreactors, gels, scaffold-free platforms, microchips, and other technologies. The market, based on application, has been divided into research, drug discovery, tissue engineering, clinical applications, stem cell biology, and other applications. Based on end user, the market has been segregated into research laboratories and institutes, biotechnology and pharmaceutical industries, hospitals and diagnostic centers, and others end users.
Key Market Trends
Drug Discovery Segment is Expected to Exhibit the Fastest Growth Rate Over the Forecast Period
Conventionally, drug discovery has been carried out using animal models. However, with the explosion of drug molecules synthesized/discovered in the past two decades, there has been a growth in high-throughput screening. Consequently, drug discovery has become a process that was time-resource intensive. Additionally, animal testing is subject to ethical controversies. Consequently, the demand for alternative methods for drug testing and drug discovery processes has gained momentum.
A specific application of 3D cell culture in drug discovery is organ-on-chips. These systems are being extensively employed by cancer therapeutic manufacturers for improving the benefit-risk balance by targeting precisely a particular cell type, a defined biomechanism, or a precise receptor. The current up-trend in cancer therapeutics’ research is likely to further spur the application of 3D cell cultures in drug discovery. Over the forecast period, much novel cancer therapeutics are expected to receive market approval, which is likely to, in turn, drive the growth of the 3D cell culture market.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America dominated the overall 3D cell culture market with the United States accounting as the major contributor to the market. The United States is focusing more on R&D and is currently spending a lot on it. This has resulted in increasing technological advancements in the country. Many American applicants feature among the main patent applicants for the 3D cell culture domain. American applicants tend to develop their technologies in the United States, as well as in Asia. In 2016, an international collaboration between the United States, the United Kingdom, and the Netherlands, cancer-research heavy-weights, aimed to grow 1,000 new cell lines for scientists to study. The project is also expected to use cutting-edge techniques to generate its models, which will include 3D cultures called organoids, and cells that have been reprogrammed to grow indefinitely in culture. ICTDCCS 2018, 20th International Conference on 3D Cell Culture Systems, was held in Boston (the United States) on April 23-24, 2018. These factors have augmented the US 3D cell culture market and it is expected to further increase in the future.
Competitive Landscape
The 3D cell culture market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as 3D Biomatrix, Reinnervate Ltd, 3D Biotek LLC, Becton, Dickinson and Company, and Sigma Aldrich Corporation, is in turn, increasing the overall competitive rivalry in the market. Product advancements and improvement in the 3D cell culture technology by the major players are increasing the competitive rivalry.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Introduction to Market Drivers and Restraints
4.3 Market Drivers
4.3.1 Huge R&D Investment by Life Science Companies
4.3.2 Development of Automated Large-scale Cell Culture Systems
4.3.3 Rising Need for Organ Transplantation
4.3.4 Use of 3D Cell Culture Models as Alternative Tools for In Vivo Testing
4.3.5 Increasing Focus on Regenerative Medicine
4.4 Market Restraints
4.4.1 Lack of Experienced and Skilled Professionals
4.4.2 Budget Restriction for Small- and Medium-sized Laboratories
4.4.3 Lack of Consistency in 3D Cell Culture Products
4.4.4 Stringent Process Controls for Advanced Handling Capabilities
4.5 Industry Attractiveness- Porter’s Five Forces Analysis
4.5.1 Threat of New Entrants
4.5.2 Bargaining Power of Buyers/Consumers
4.5.3 Bargaining Power of Suppliers
4.5.4 Threat of Substitute Products
4.5.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Extracellular Matrices (Scafffolds)
5.1.2 Bioreactors
5.1.3 Gels
5.1.4 Scaffold-free Platforms
5.1.5 Microchips
5.1.6 Other Technologies
5.2 By Application
5.2.1 Research
5.2.2 Drug Discovery
5.2.3 Tissue Engineering
5.2.4 Clinical Applications
5.2.5 Stem Cell Biology
5.2.6 Other Applications
5.3 By End User
5.3.1 Research Laboratories and Institutes
5.3.2 Biotechnology and Pharmaceutical Companies
5.3.3 Hospitals and Diagnostic Centers
5.3.4 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 UK
5.4.2.2 Germany
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 3D Biotek LLC
6.1.2 Becton Dickinson and Company
6.1.3 Sigma Aldrich Corporation
6.1.4 Corning Incorporated
6.1.5 Thermo Fisher Scientific
6.1.6 Global Cell Solutions Inc.
6.1.7 Nanofiber Solutions Incorporation
6.1.8 Insphero AG
6.1.9 Lonza Group
6.1.10 Nano 3D Biosciences
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technology
Extracellular Matrices (Scafffolds)
Bioreactors
Gels
Scaffold-free Platforms
Microchips
Other Technologies
By Application
Research
Drug Discovery
Tissue Engineering
Clinical Applications
Stem Cell Biology
Other Applications
By End User
Research Laboratories and Institutes
Biotechnology and Pharmaceutical Companies
Hospitals and Diagnostic Centers
Other End Users
Geography
North America
US
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Veterinary Services Market- Growth, Trends, and Forecast (2019 – 2024)
| Animal Nutrition & Wellness | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 13-06-2019 |
- Animal Nutrition & Wellness
- Mordor Intelligence
- 115 pages
- Published: 13-06-2019
Market Overview
The veterinary services market was valued at USD 94.14 billion in 2018, and it is estimated to be valued at USD 138.66 billion in 2024, while witnessing a CAGR of 6.67% over the forecast period of 2019-2024. Increase in animal adoption, rise in prevalence of animal diseases, better animal health awareness, and increase in R&D and government initiatives are the key factors propelling the growth of the market, globally.
A significant rise in the adoption of pet animals, including dogs, cats, and even horses, as companions for human beings, has been observed over the recent years. Moreover, farm animals, including cattle and swine, have also been taken in for various commercial purposes in the recent years. The developed countries represent a significantly large share in companion animal-ownership, owing to the favorable economic condition and several other factors. This rise in both companion, as well as livestock animal adoption, along with the increased per capita animal health expenditure, indirectly generates an increase in the demand for proper veterinary services. In addition to the aforementioned factor, the rise in prevalence of various animal diseases, growth in animal health awareness, and increase in R&D and government initiatives are expected to propel the market growth, over the forecast period.
Scope of the Report
Veterinary services refer to all kinds of facilities, solutions, systems, and services targeted at animal health welfare, including hospitalization, dentistry, diagnostics, surgery, nursing, medication, medical devices, specialist referral, alternative therapies, and behavioral therapies performed by a veterinarian.
Key Market Trends
Companion Animal Segment by Animal Type is Expected to Hold the Largest Market Share
The companion animal segment in the veterinary services market is believed to have the largest market size, and the segment is expected to witness a CAGR of 6.79% during the forecast period.
In today’s era, small animal surgery is moving forward, taking advantage of the developments and achievements in human surgery. Cardiovascular operations, tracheal and urethral stenting, advances in surgical oncology, total hip replacement, developments in neurosurgery, and kidney transplantation in cats are among the new modalities. They can be used for small animal patients, in order to provide them advanced veterinary care and to improve their quality of life, as well as increase their life expectancy. The number of dogs and cats euthanized in US shelters, annually, has declined from approximately 2.6 million in 2011 to 1.5 million currently. This decline can be partially explained by an increase in the percentage of animals adopted and an increase in the number of stray animals successfully returned to their owners.
Increased adoption of companion animals as pets in developed regions and increasing awareness regarding pet health are expected to drive the veterinary services market during the forecast period.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America currently dominates the veterinary services market and is expected to continue its stronghold for a few more years. The United States is expected to retain its significant market share, owing to factors, such as rising pet adoption and increasing per capita animal healthcare expenditure. Besides, a rise in the prevalence of various animal diseases is identified as a significant driving factor for the market growth. Also, the rising awareness about animal health, favorable and advanced healthcare IT infrastructure, effective initiatives by the government, and rise in pet adoption are some of the other significant factors that are driving the growth of the North American veterinary services market.
Competitive Landscape
The veterinary services market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. Companies, like CVS Group PLC, Ethos Veterinary Health, Idexx laboratories, National Veterinary Care Ltd, and Mars Inc., hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Service
5.1.1 Surgery
5.1.2 Diagnostic Tests and Imaging
5.1.3 Physical Health Monitoring
5.1.4 Other Services (Dental Care, Grooming, Vaccination, Counselling, etc.)
5.2 Animal Type
5.2.1 Companion Animal
5.2.2 Farm Animal
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 CVS Group PLC
6.1.2 Ethos Veterinary Health
6.1.3 Greencross Limited
6.1.4 Idexx laboratories
6.1.5 Mars Inc.
6.1.6 National Veterinary Care Ltd
6.1.7 Patterson Companies Inc.
6.1.8 Pets at Home Group PLC
6.1.9 Animart LLC
6.1.10 Vetronic Services Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Service
Surgery
Diagnostic Tests and Imaging
Physical Health Monitoring
Other Services (Dental Care, Grooming, Vaccination, Counselling, etc.)
Animal Type
Companion Animal
Farm Animal
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America